2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Merck company profile · business segments · history · financial snapshot · S&P 500 rank #30 · 默克公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | MRK (NYSE) |
| Company | Merck & Co., Inc. |
| GICS sector / industry | Health Care (XLV) / Pharmaceuticals |
| S&P 500 rank (by weight) | #30 · 0.52% (Oct 23, 2026) |
| Sector rank (by weight) | #5 of 60 in Health Care (Oct 23, 2026) |
| Headquarters | Rahway, New Jersey (126 East Lincoln Avenue) |
| Founded | 1891, New York |
| CEO | Robert M. Davis (chairman, chief executive officer and president) |
| Employees | Approximately 75,000 worldwide, including approximately 30,000 in the U.S. (Dec 31, 2025, FY2025 10-K) |
| Market cap | ≈$358B (Oct 23, 2026) |
| SEC filings | EDGAR — CIK 0000310158 |
WHAT IT DOES
Merck & Co., Inc. is a global health care company that delivers innovative health solutions through prescription medicines, including biologic therapies, vaccines and animal health products. Its one-line model: discover, develop and sell patent-protected prescription medicines and vaccines, led by oncology, and use the cash they generate to fund the next generation of medicines.
Merck & Co., Inc. (US, NYSE: MRK) is distinct from Merck KGaA (Germany). The two companies are separate companies with separate ownership, operations and financial results, and they share only a historical name origin. Outside the United States and Canada, Merck & Co., Inc. operates under the name MSD. All figures in this profile are for Merck & Co., Inc. only.
The commercial engine is the Pharmaceutical segment, which sells human health pharmaceutical and vaccine products, mainly by prescription, to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. Its largest product by far is Keytruda, an anti-PD-1 cancer therapy, with FY2025 sales of $31.68B. The second reported segment, Animal Health, sells veterinary pharmaceuticals, vaccines and digitally connected identification, traceability and monitoring products for livestock and companion animals.
Revenue is therefore concentrated in a small number of patented products, and the business model depends on replacing sales lost to patent expiry with new approvals and acquisitions. In FY2025 the company completed the acquisition of Verona Pharma, paying $10.042B in cash net of cash acquired, gaining a marketed treatment for chronic obstructive pulmonary disease.
BUSINESS SEGMENTS — FY2025
| Segment | Sales | Share |
|---|---|---|
| Pharmaceutical | $58.142B | 89.4% |
| Animal Health | $6.354B | 9.8% |
| Other revenues | $0.515B | 0.8% |
| Total | $65.011B | 100% |
Pharmaceutical ($58.142B, 89.4% of total sales). Human health pharmaceutical and vaccine products, led by Keytruda at $31.68B and Gardasil/Gardasil 9 at $5.233B in FY2025. Oncology, vaccines, cardiometabolic and other therapeutic areas sit inside this segment.
Animal Health ($6.354B, 9.8% of total sales). Veterinary pharmaceuticals and vaccines, plus health management solutions and services, for livestock and companion animals. Within the segment, livestock sales were $3.896B in FY2025 on the product-sales table in the 10-K, with the balance in companion animals; those two product lines are shown here only as context, not as a second segment split.
HISTORY
| Year | Milestone |
|---|---|
| 1891 | Established in New York as the United States business associated with the German Merck enterprise |
| 1919 | Repurchased by George Merck after seizure by the United States government during World War I, becoming an independent American company |
| 1953 | Merged with Sharp & Dohme, forming Merck Sharp & Dohme |
| 2004 | Vioxx withdrawn from the market worldwide after safety concerns, a major reputational and financial setback |
| 2009 | Completed the merger with Schering-Plough in November, keeping the Merck name |
| 2014 | Keytruda (pembrolizumab) approved by the United States Food and Drug Administration, first for melanoma |
| 2021 | Robert M. Davis becomes chief executive officer in July, succeeding Kenneth Frazier |
| 2025 | Keytruda Qlex, a subcutaneous formulation of Keytruda, approved by the United States Food and Drug Administration in September across most adult solid tumor indications for Keytruda |
| 2025 | Completed the acquisition of Verona Pharma in October |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2025
| Sales | $65.011B (+1.3% vs FY2024) |
| Cost of sales | $16.382B |
| Gross profit | $48.629B · 74.8% margin |
| Research and development | $15.789B |
| Selling, general and administrative | $10.733B |
| Income before taxes | $21.067B |
| Net income attributable to Merck & Co., Inc. | $18.254B · 28.1% margin |
| Operating cash flow | $16.472B |
| Capital expenditures | $4.112B |
| Cash and cash equivalents | $14.565B (Dec 31, 2025) |
| Long-term debt | $46.750B (Dec 31, 2025) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Merck is a Health Care (XLV) constituent ranked #30 in the S&P 500 by weight at 0.52%, and #5 of 60 in Health Care, as of Oct 23, 2026. At that weight, a 1% move in MRK alone moves the S&P 500 by roughly 0.5 basis points before any read-through to pharmaceutical peers, so Merck is a sector bellwether rather than an index driver.
For index watchers, Merck matters in a different way: it is one of the largest pure pharmaceutical names in the index, so its Keytruda cycle, vaccine demand and patent-expiry calendar are read as signals for the whole Health Care sector, for drug-pricing policy, and for how much of the index's earnings growth is tied to a single patented product.
SOURCES & METHODOLOGY
| Financials, segments, employees, headquarters, CEO | Merck FY2025 Form 10-K (filed Feb 24, 2026; fiscal year ended Dec 31, 2025) |
| Index weight & ranks | Slickcharts S&P 500 weights, Oct 23, 2026 close, as given in the dispatch baseline |
| Keytruda patent and price-setting statements | Merck FY2025 Form 10-K, Item 1 and Item 7 risk and patent disclosures |
| History milestones | Company history as reported in established secondary coverage; 2009 merger and 2014 Keytruda approval are widely reported public events |
| Logo | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. |
| Market cap | ≈$358B (Oct 23, 2026) |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | MRK(NYSE) |
| 公司 | Merck & Co., Inc.(默克) |
| GICS 板塊/行業 | 醫療健康(XLV)/製藥 |
| 標普500排名(按權重) | #30 · 0.52%(2026年10月23日) |
| 板塊內排名(按權重) | 醫療健康 #5 of 60(2026年10月23日) |
| 總部 | 新澤西州拉威(126 East Lincoln Avenue) |
| 成立 | 1891年,紐約 |
| 執行長 | Robert M. Davis(董事長、首席執行官兼總裁) |
| 員工 | 全球約75,000名,其中美國約30,000名(2025年12月31日,FY2025 10-K) |
| 市值 | ≈$358B(2026年10月23日) |
| SEC 申報 | EDGAR — CIK 0000310158 |
業務概覽
默克是一家全球醫療健康公司,透過處方藥(包括生物製劑)、疫苗與動物健康產品提供創新健康方案。一句話商業模式:發現、開發並銷售受專利保護的處方藥與疫苗,以腫瘤藥為首,再用其現金流資助下一代藥物。
Merck & Co., Inc.(美國,NYSE:MRK)與 Merck KGaA(德國)不同。兩家公司是各自獨立的公司,擁有權、營運與財務結果各不相同,僅有歷史名稱淵源。在美國與加拿大以外,Merck & Co., Inc. 以 MSD 之名營運。本篇所有數字皆僅屬 Merck & Co., Inc.。
商業引擎是製藥板塊,銷售人類健康處方藥與疫苗產品,主要經處方銷售給藥品批發商與零售商、醫院、政府機構與管理式醫療機構。其最大產品是抗 PD-1 癌症療法 Keytruda,FY2025 銷售額為 $31.68B(316.8億美元)。第二個申報板塊動物健康,則銷售獸用藥品、疫苗,以及用於牲畜與伴侶動物的數位連結識別、追溯與監測產品。
因此收入集中於少數專利產品,業務模式取決於以新批准與收購取代專利到期後失去的銷售。FY2025 公司完成了 Verona Pharma 收購,扣除取得現金後以現金支付 $10.042B(100.42億美元),取得一款慢性阻塞性肺病上市治療藥物。
業務板塊 — FY2025
| 板塊 | 銷售額 | 佔比 |
|---|---|---|
| 製藥 | $58.142B(581.42億美元) | 89.4% |
| 動物健康 | $6.354B(63.54億美元) | 9.8% |
| 其他收入 | $0.515B(5.15億美元) | 0.8% |
| 合計 | $65.011B(650.11億美元) | 100% |
製藥($58.142B(581.42億美元),佔總銷售額 89.4%)。人類健康處方藥與疫苗產品,以 Keytruda $31.68B(316.8億美元)與 Gardasil/Gardasil 9 $5.233B(52.33億美元)為首(FY2025)。腫瘤、疫苗、心臟代謝及其他治療領域皆屬此板塊。
動物健康($6.354B(63.54億美元),佔總銷售額 9.8%)。獸用藥品與疫苗,以及健康管理方案與服務,服務牲畜與伴侶動物。板塊內牲畜銷售額在 10-K 產品銷售表中為 $3.896B(38.96億美元),其餘為伴侶動物;此處僅作背景,不作第二層板塊拆分。
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1891 | 在紐約成立,為與德國 Merck 企業相關的美國業務 |
| 1919 | 第一次世界大戰期間遭美國政府徵收後,由 George Merck 回購,成為獨立的美國公司 |
| 1953 | 與 Sharp & Dohme 合併,組成 Merck Sharp & Dohme |
| 2004 | Vioxx 因安全疑慮在全球撤市,是重大的聲譽與財務挫折 |
| 2009 | 11月完成與 Schering-Plough 的合併,保留 Merck 之名 |
| 2014 | Keytruda(pembrolizumab)獲美國食品藥物管理局批准,首用於黑色素瘤 |
| 2021 | Robert M. Davis 於 7 月出任首席執行官,接替 Kenneth Frazier |
| 2025 | Keytruda 皮下注射劑型 Keytruda Qlex 於 9 月獲美國食品藥物管理局批准,適用於 Keytruda 大多數成人實體腫瘤適應症 |
| 2025 | 10月完成 Verona Pharma 收購 |
競爭地位
財務快照 — FY2025
| 銷售額 | $65.011B(650.11億美元)(較 FY2024 增長 1.3%) |
| 銷售成本 | $16.382B(163.82億美元) |
| 毛利 | $48.629B(486.29億美元)· 毛利率 74.8% |
| 研發 | $15.789B(157.89億美元) |
| 銷售、一般與行政費用 | $10.733B(107.33億美元) |
| 稅前利潤 | $21.067B(210.67億美元) |
| 歸屬 Merck & Co., Inc. 的淨利潤 | $18.254B(182.54億美元)· 淨利率 28.1% |
| 經營現金流 | $16.472B(164.72億美元) |
| 資本支出 | $4.112B(41.12億美元) |
| 現金及現金等值物 | $14.565B(145.65億美元)(2025年12月31日) |
| 長期債務 | $46.750B(467.5億美元)(2025年12月31日) |
主要風險
對標普500的重要性
默克是醫療健康(XLV)成分股,按權重在標普500 排名 #30,權重 0.52%,在醫療健康板塊排名 #5 of 60,截至 2026 年 10 月 23 日。按此權重,MRK 單獨波動 1%,標普500 大約動 0.5 個基點,還未計入對製藥同業的連動,因此默克是板塊風向標,而非指數驅動者。
對指數觀察者而言,默克的重要性在另一層面:它是標普500 中最大的純製藥公司之一,因此其 Keytruda 週期、疫苗需求與專利到期日程,被視為整個醫療健康板塊、藥品定價政策,以及指數盈利增長中有多少繫於單一專利產品的訊號。
來源與方法
| 財務、板塊、員工 | Merck FY2025 Form 10-K(2026年2月24日申報;會計年度截至2025年12月31日) |
| 指數權重與排名 | Slickcharts 標普500權重,2026年10月23日收盤,依派工基線表 |
| Keytruda 專利與定價陳述 | Merck FY2025 Form 10-K,Item 1 與 Item 7 風險與專利披露 |
| 歷史里程碑 | 既有二手報導中的公司歷史;2009 年合併與 2014 年 Keytruda 批准為廣泛報導的公開事件 |
| Logo | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 |
| 市值 | ≈$358B(2026年10月23日) |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-10-25 06:16 · updated 2026-11-14 23:50 · rev 9